CN105412281A - Traditional Chinese medicinal composition for treating allergic asthma and preparation method thereof - Google Patents
Traditional Chinese medicinal composition for treating allergic asthma and preparation method thereof Download PDFInfo
- Publication number
- CN105412281A CN105412281A CN201510885057.9A CN201510885057A CN105412281A CN 105412281 A CN105412281 A CN 105412281A CN 201510885057 A CN201510885057 A CN 201510885057A CN 105412281 A CN105412281 A CN 105412281A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- clear paste
- chinese medicine
- allergic asthma
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 201000009961 allergic asthma Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 14
- 210000000582 semen Anatomy 0.000 claims abstract description 35
- 241000628997 Flos Species 0.000 claims abstract description 18
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 18
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 241000218628 Ginkgo Species 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 229920000858 Cyclodextrin Polymers 0.000 claims description 7
- 239000001116 FEMA 4028 Substances 0.000 claims description 7
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 7
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 7
- 229960004853 betadex Drugs 0.000 claims description 7
- 238000002481 ethanol extraction Methods 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 7
- 238000001256 steam distillation Methods 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 239000000341 volatile oil Substances 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 208000000059 Dyspnea Diseases 0.000 abstract description 3
- 206010013975 Dyspnoeas Diseases 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 206010028748 Nasal obstruction Diseases 0.000 abstract description 2
- 206010043089 tachypnoea Diseases 0.000 abstract description 2
- 241001662414 Aster tataricus Species 0.000 abstract 1
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 235000004347 Perilla Nutrition 0.000 abstract 1
- 244000124853 Perilla frutescens Species 0.000 abstract 1
- 244000018633 Prunus armeniaca Species 0.000 abstract 1
- 235000009827 Prunus armeniaca Nutrition 0.000 abstract 1
- 208000005392 Spasm Diseases 0.000 abstract 1
- 230000000881 depressing effect Effects 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 13
- 229940079593 drug Drugs 0.000 description 8
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 102000004388 Interleukin-4 Human genes 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 210000003714 granulocyte Anatomy 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000003448 neutrophilic effect Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- -1 mixing Substances 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000002052 anaphylactic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 208000035742 Air-borne transmission Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 108010015268 Integration Host Factors Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000005557 airborne transmission Effects 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 230000008372 airway inflammatory response Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000010540 rapid respiration Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a traditional Chinese medicinal composition for treating allergic asthma, which is prepared from radix saposhnikoviae, perilla leaf, roasted herba ephedrae, fructus schisandrae, semen ginkgo, apricot, tatarian aster root, common macrocarpium fruit, flos magnoliae and the like. The prescription is suitable for the disease: allergic asthma; on one hand, the traditional Chinese medicinal composition has the efficacy of dispelling wind and dispersing lung Qi, namely, relieving airway spasm in the aspect of airway, and relieving airway high reaction; and on the other hand, the traditional Chinese medicinal composition has the efficacy of promoting the restoration of consciousness and depressing Qi and relieving asthma, and has the purifying and descending function of the lung aiming at nasal obstruction, polypnea and syndrome characterized by dyspnea.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of Chinese medicine composition for the treatment of allergic asthma and preparation method thereof.
Background technology
Bronchial asthma is the chronic airway inflammation disease participated in by various kinds of cell and cellular component, this chronic inflammatory disease is relevant to airway hyperreactivity, the reversible airflow limitation that usual appearance is extensive and changeable, cause the symptoms such as the panting of recurrent exerbation, tachypnea, uncomfortable in chest and (or) cough, how in night and (or) outbreak in early morning, aggravation.Time serious, whole body is livid purple, and serious patient respiratory sound can suddenly disappear.
The risk factor of asthma comprises host factor (inherited genetic factors) and environmental factors two aspects.Inherited genetic factors can embody with it a lot of patient, in the middle of the relatives of such as most patient (have relationship by blood, nearly three generations people), asthma (recurrent cough, pant) or other anaphylactic diseases (allergic rhinitis, atopic dermatitis) medical history can be traced back to.Most of asthmatic patient belongs to allergic constitution, itself may with allergic rhinitis and atopic dermatitis, or the allergen (acarid, pollen, house pet, mycete etc.), some food (nut, milk, Semen arachidis hypogaeae, seafood etc.), drug allergy etc. to common air-borne transmission.
At present, Chinese medicine still belongs to blank in treatment allergic asthma field, and the present invention, on summary Comprehensive Treatment success and failure experiential basis, follows modern Chinese medicine theory, through lot of experiments research, finds a kind of Chinese medicine composition of effective treatment allergic asthma.
Summary of the invention
The object of this invention is to provide a kind of Chinese medicine composition for the treatment of allergic asthma.
Another object of the present invention is to provide the preparation method of the Chinese medicine composition of this treatment allergic asthma.
The object of the invention is to realize in the following manner:
Treat a Chinese medicine composition for allergic asthma, said composition is made up of the component of following weight portion:
Radix Saposhnikoviae 10-15 weight portion, Folium Perillae 10-15 weight portion, Herba Ephedrae (processed) 2-6 weight portion, Fructus Schisandrae Chinensis 7-9 weight portion, Semen Ginkgo 7-9 weight portion, Semen Armeniacae Amarum 7-9 weight portion, Radix Asteris 7-9 weight portion, Fructus Corni 7-9 weight portion, Flos Magnoliae 7-9 weight portion.
The Chinese medicine composition of above-mentioned treatment allergic asthma is preferably made up of the component of following weight portion:
Radix Saposhnikoviae 10-12 weight portion, Folium Perillae 10-12 weight portion, Herba Ephedrae (processed) 4-6 weight portion, Fructus Schisandrae Chinensis 7-8 weight portion, Semen Ginkgo 7-8 weight portion, Semen Armeniacae Amarum 7-8 weight portion, Radix Asteris 7-8 weight portion, Fructus Corni 7-8 weight portion, Flos Magnoliae 7-8 weight portion.
The Chinese medicine composition of above-mentioned treatment allergic asthma is most preferably made up of the component of following weight portion:
Radix Saposhnikoviae 10 weight portion, Folium Perillae 10 weight portion, Herba Ephedrae (processed) 6 weight portion, Fructus Schisandrae Chinensis 8 weight portion, Semen Ginkgo 8 weight portion, Semen Armeniacae Amarum 8 weight portion, Radix Asteris 8 weight portion, Fructus Corni 8 weight portion, Flos Magnoliae 8 weight portion.
The Chinese medicine composition that the present invention treats allergic asthma adds the adjuvant that pharmacy allows and prepares granule, capsule, tablet or pill.
The preparation method of Chinese medicine composition of the present invention comprises the steps:
By Folium Perillae, Flos Magnoliae extraction by steam distillation volatile ingredient, for subsequent use after adopting beta-cyclodextrin inclusion compound, medicinal residues and Radix Saposhnikoviae, Herba Ephedrae (processed), Semen Armeniacae Amarum merge, decoct with water 1-3 time respectively, each 1-3 hour, merge extractive liquid, being condensed into relative density under 50 DEG C of conditions is the clear paste of 1.10 ~ 1.15, alcohol is sink to alcohol content 60%-70%, get supernatant concentration make relative density under 50 DEG C of conditions be 1.25 ~ 1.30 clear paste for subsequent use; Fructus Schisandrae Chinensis, Semen Ginkgo, Radix Asteris, Fructus Corni 60%-70% ethanol extraction 1-3 time, each 1-3 hour, merges alcohol extract, and concentrated to make relative density under 50 DEG C of conditions be the clear paste of 1.25 ~ 1.30; Merged by above-mentioned each clear paste, dry, pulverize, add volatile oil clathrate compound, mixing, to obtain final product.
The preparation method of above-mentioned Chinese medicine composition specifically comprises the steps:
By Folium Perillae, Flos Magnoliae extraction by steam distillation volatile ingredient, for subsequent use after adopting beta-cyclodextrin inclusion compound, medicinal residues and Radix Saposhnikoviae, Herba Ephedrae (processed), Semen Armeniacae Amarum merge, add 10 times amount soak by water 3 times respectively, each 1.5 hours, merge extractive liquid, being condensed into relative density under 50 DEG C of conditions is the clear paste of 1.10 ~ 1.15, alcohol is sink to alcohol content 70%, get supernatant concentration make relative density under 50 DEG C of conditions be 1.25 ~ 1.30 clear paste for subsequent use; Fructus Schisandrae Chinensis, Semen Ginkgo, Radix Asteris, Fructus Corni 60% ethanol extraction three times, each 2.5 hours, merge alcohol extract, and concentrated to make relative density under 50 DEG C of conditions be the clear paste of 1.25 ~ 1.30; Merged by above-mentioned each clear paste, dry, pulverize, add volatile oil clathrate compound, mixing, to obtain final product.
Chinese medicine composition of the present invention application in the medicine of preparation treatment allergic asthma has significant effect.
The treatment of the present composition from two aspects for allergic asthma, one dispelling wind dispersing and lowering lung-QI, namely improves air flue contraction anxious, to airway hyper-reaction with the effect of releiving from air flue aspect of releiving; Namely it two be sensible lowering the adverse-rising QI to subdue asthma, for nasal obstruction, out of breath, dyspnea with rapid and short breath, improves the respectful of lung and fall function.
Inventor defines the aggregate analysis to asthma clinically, and is analyzed according to current bronchial wheezing diagnosis and treatment aspect, thinks and the understanding of " asthma of heat type, asthma of cold-type, centered by expectorant, latent phlegm is long-standing expectorant " receives publicity always, and textbook, many treatises are all proved repeatedly.And namely another group has intolerance factors basis, very cause and have physiques and natural endowment, " wind heavy breathing " that familial factor patient occupies larger proportion also feels demonstration seldom, and from wind opinion, the person of controlling is more inadequate, repeatedly studies and has carried out again screening determining this prescription according to clinical application.
In the party with Radix Saposhnikoviae, Folium Perillae for monarch, it is intended to the meaning of dispelling wind, antiallergic, two medicines also clinical formation from wind opinion control.Radix Saposhnikoviae, dispelling wind dispels the wind, effective in cure to respiratory system anaphylactic disease.Folium Perillae, dispelling wind, more to the application of air flue illness class, the two all has the merit of dispelling wind and ventilating the lung, antiallergic emergency;
In side, Herba Ephedrae (processed), Radix Asteris, Semen Armeniacae Amarum are ministerial drug, and Herba Ephedrae is dispelling wind sending down the abnormal ascending QI and the big medicine of depressed lung-energy dispersing, treats key medicine of breathing heavily heavy breathing uncomfortable in chest, have expert to be also once apt to treat with Herba Ephedrae the experience of asthma; Radix Asteris, Semen Armeniacae Amarum declare the gas of respectful lung especially, nourishing the lung to keep the adverse QI downward, to feel suffocated dyspnea with rapid respiration and use, help Herba Ephedrae to tackle asthma attack altogether for asthma, or chronic sustained and controlling;
In side Semen Ginkgo, Fructus Schisandrae Chinensis, Fructus Corni all have improving inspiration by invigorating kidney-QI to astringe the lung, the effect of air flue of releiving, for medicine that clinical airway hyper-reaction is selected to help monarch, ministerial drug in the hope of sending down the abnormal ascending QI, improving inspiration by invigorating kidney-QI, to astringe the lung, Dingchuan, three medicines are adjuvant drug;
Flos Magnoliae, dispelling wind is sensible, also has the curative effect of antiallergic, gets it for making medicine.
Full side did not belong to cold, overheated side, and side be cold not hot, and namely " Xin Pingwei master " is to control ailment said due to cold or exposure for suffering from, in order to air flue of releiving, dispersing and lowering lung-QI, nurse one's health respectful fall not normal, relieving asthma and double sensible be method, see that the treatment of wind card person is always anticipated to tackle asthma.
Detailed description of the invention
Set forth the beneficial effect of medicine of the present invention further below by way of test example, these test examples comprise acute toxicity testing and the pharmacodynamics test of medicine of the present invention (hereinafter referred to as asthma side).
One, effect experiment:
1, material
1.1 by reagent
Asthma side: prepare according to embodiment 1 method.
1.2 contrast medicines
Dexamethasone acetate tablets: specification 0.75mg/ sheet, lot number: 130125201, Cisen Pharmaceutical Co., Ltd.
1.3 animal
SD rat 50, male, body weight 180 ~ 200g, cleaning grade, the western general and-Bi Kai laboratory animal company limited in Shanghai, the quality certification number: (Shanghai) 2008-0016.
1.4 reagent
Ovalbumin OVA, article No.: A5503, (sigma); Aluminium hydroxide Al (OH)
3, article No. 239186, (sigma); IL-4, IFN-γ and TGF-β 1 test kit, lot number 20141120, provided by Beijing China English biotechnology research.
2, experimental technique
2.1 rat allergic asthma models are set up
60 rats are divided into Normal group, asthmatic model group and Dexamethasone group 16.2mg/kg, the high, medium and low dosage group in asthma side at random, and dosage is respectively 14g/kg, 7g/kg, 3.5g/kg.By the method that Vanacker etc. reports, asthmatic model Mus mixes liquid (OVA1mg, aluminium hydroxide 200 μ g, is dissolved in 1ml normal saline and is made into suspension) sensitization at d0 and d7 every intraperitoneal injection antigen.D14 starts with 1%OVA Ultrasonic atomising taring and excites, every two days 1 time, each 30min, totally 2 weeks.Rats in normal control group is in d0 and d7 1ml normal saline intraperitoneal injection, and d14 starts to use normal saline Ultrasonic atomising taring, every two days 1 time, each 30min, totally 2 weeks.Dexamethasone group and asthma side its d14 of group rat start gavage and give relative medicine, 1ml/100g, totally 2 weeks.Normal group and asthmatic model group rat give equivalent CMC-Na solution in d14 gavage, totally 2 weeks.
2.2 Indexs measure
2.2.1 bronchoalveolar lavage (BALF) and collection of specimens
After each group of rat excites 1h for the last time, every rat is with after 10% chloral hydrate 35mg/kg intraperitoneal injection of anesthesia, and abdominal aortic blood is lethal.Sterilize and open thoracic cavity, ligation right main bronchus, inserting trachea with tracheal intubation pin, after fixing, row left pulmonary alveolar wass art.Slow injection D-hanks liquid 5ml stops 10s, and slow pumpback, repeats 3 times; Ethylene recov is about 4ml.Ethylene recov injects EP pipe immediately, 4 DEG C of centrifugal 15min of 1500r/min.Get acclimatization and make cell smear, Rui Shi-Ji Mu Safa dyes, and carries out cell divide by morphological criteria.After remaining precipitation 4ml normal saline dilutes again, add blood cell counting plate, make cell counting under the microscope.
2.2.2 IL-4, IFN-γ and TGF-β 1 level in serum
After each group of rat excites 24h for the last time, every rat with after 10% chloral hydrate 35mg/kg intraperitoneal injection of anesthesia, abdominal aortic blood, 4 DEG C of centrifugal 10min of 3000r/min, separation of serum.
2.3 statistical procedures side operator according to this,
represent, use SPSS17.0 statistical software to adopt one factor analysis of variance to carry out statistical procedures.
3, experimental result
Total white blood cells, neutrophilic granulocyte percentage test in 3.1BALF
Table 1 asthma side on the impact of total white blood cells, neutrophilic granulocyte percentage ratio in BALF (
n=10)
Note: compare with Normal group,
△p < 0.05,
△ △p < 0.01; Compare with model group,
#p < 0.05,
##p < 0.01.
Compared with normal group, in model group rats BALF, total white blood cells and neutrophilic granulocyte percentage ratio obviously raise (P<0.01), compare with model group, the high, medium and low dosage group in asthma side can reduce total white blood cells and neutrophilic granulocyte percentage ratio, significant difference (P<0.05).
IL-4, IFN-γ and TGF-β 1 level in 3.2 serum
Table 2 asthma side on the impact of IL-4, IFN-γ and TGF-β 1 level in serum (
n=10)
Note: compare with Normal group,
△p < 0.05,
△ △p < 0.01; Compare with model group,
#p < 0.05,
##p < 0.01.
Compared with normal group, in model group rats serum, IL-4, IFN-γ and TGF-β 1 level significantly raises (P<0.01), compare with model group, the high, medium and low dosage group in asthma side can reduce IL-4, IFN-γ and TGF-β 1 level (P<0.01, P<0.05).
This result of the test shows, the Airway inflammatory response of asthma side to rat asthma animal model has obvious inhibitory action, can reduce total white blood cells and neutrophilic granulocyte percentage ratio in BALF, reduces serum IL-4, IFN-γ and TGF-β 1 level.
Two, acute toxicity testing:
ICR mice 40, female, tom is divided into 2 groups by body weight equilibrium respectively, often organizes each 10 of male and female, is respectively matched group and administration group; Administration group Mouse oral asthma side 400g crude drug/kg, the oral constant volume test water of matched group, administration volume 40mL/kg, point 2 administrations morning and afternoon, twice dosing interval is in 4 ~ 5h.Administration group and matched group are all dying or dead without animal, and mice single oral asthma granule maximum tolerated dose (MTD) is 400g crude drug/kg, is about 325 times of clinical plan dosage.
The preparation of embodiment 1 medicinal granule of the present invention
Above nine tastes, Folium Perillae, Flos Magnoliae extraction by steam distillation volatile ingredient, for subsequent use after adopting beta-cyclodextrin inclusion compound, medicinal residues and Radix Saposhnikoviae, Herba Ephedrae (processed), Semen Armeniacae Amarum merge, and add 10 times amount soak by water three times respectively, each 1.5 hours, merge extractive liquid, is condensed into clear paste (d=1.10 ~ 1.15,50 DEG C), alcohol is sink to alcohol content 70%, and getting supernatant concentration, to make relative density be that the clear paste of 1.25 ~ 1.30 (50 DEG C) is for subsequent use; Fructus Schisandrae Chinensis, Semen Ginkgo, Radix Asteris, Fructus Corni 60% ethanol extraction three times, each 2.5 hours, merge alcohol extract, concentratedly makes the clear paste that relative density is 1.25 ~ 1.30 (50 DEG C); Above-mentioned each clear paste is merged, dry, pulverize, add volatile oil clathrate compound mixing, then with appropriate customary adjuvant, mixing, granulates, makes 1000g, to obtain final product.Day for human beings dose: 15g-30g.
The preparation of embodiment 2 medicine decoction of the present invention
Radix Saposhnikoviae 10g, Folium Perillae 10g, Herba Ephedrae (processed) 6g, Fructus Schisandrae Chinensis 8g, Semen Ginkgo 8g, Semen Armeniacae Amarum 8g, Radix Asteris 8g, Fructus Corni 8g, Flos Magnoliae 8g, add 10 times amount soak by water three times, each 2.0 hours, merge decocting liquid, be condensed into clear paste (d=1.10 ~ 1.15,50 DEG C) make decoction, day takes potion.
The preparation of embodiment 3 medicinal tablet of the present invention
Radix Saposhnikoviae 150g Folium Perillae 150g Herba Ephedrae (processed) 60g Fructus Schisandrae Chinensis 70g Semen Ginkgo 70g Semen Armeniacae Amarum 70g Radix Asteris 70g Fructus Corni 70g Flos Magnoliae 70g.
Above nine tastes, Folium Perillae, Flos Magnoliae extraction by steam distillation volatile ingredient, for subsequent use after adopting beta-cyclodextrin inclusion compound, medicinal residues and Radix Saposhnikoviae, Herba Ephedrae (processed), Semen Armeniacae Amarum merge, and add 10 times amount soak by water three times respectively, each 1.5 hours, merge extractive liquid, is condensed into clear paste (d=1.10 ~ 1.15,50 DEG C), alcohol is sink to alcohol content 70%, and getting supernatant concentration, to make relative density be that the clear paste of 1.25 ~ 1.30 (50 DEG C) is for subsequent use; Fructus Schisandrae Chinensis, Semen Ginkgo, Radix Asteris, Fructus Corni 60% ethanol extraction three times, each 2.5 hours, merge alcohol extract, concentratedly makes the clear paste that relative density is 1.25 ~ 1.30 (50 DEG C); Above-mentioned each clear paste is merged, dry, pulverize, add volatile oil clathrate compound mixing, then with appropriate customary adjuvant, mixing, granulate, tabletting, makes 1000.
The preparation of embodiment 4 medicine capsule of the present invention
Radix Saposhnikoviae 120g Folium Perillae 120g Herba Ephedrae (processed) 60g Fructus Schisandrae Chinensis 80g Semen Ginkgo 80g Semen Armeniacae Amarum 80g Radix Asteris 80g Fructus Corni 80g Flos Magnoliae 80g.
Above nine tastes, Folium Perillae, Flos Magnoliae extraction by steam distillation volatile ingredient, for subsequent use after adopting beta-cyclodextrin inclusion compound, medicinal residues and Radix Saposhnikoviae, Herba Ephedrae (processed), Semen Armeniacae Amarum merge, and add 10 times amount soak by water three times respectively, each 1.5 hours, merge extractive liquid, is condensed into clear paste (d=1.10 ~ 1.15,50 DEG C), alcohol is sink to alcohol content 70%, and getting supernatant concentration, to make relative density be that the clear paste of 1.25 ~ 1.30 (50 DEG C) is for subsequent use; Fructus Schisandrae Chinensis, Semen Ginkgo, Radix Asteris, Fructus Corni 60% ethanol extraction three times, each 2.5 hours, merge alcohol extract, concentratedly makes the clear paste that relative density is 1.25 ~ 1.30 (50 DEG C); Above-mentioned each clear paste is merged, dry, pulverize, add volatile oil clathrate compound mixing, then with appropriate customary adjuvant, mixing, granulate, encapsulating capsule, makes 1000.
Claims (7)
1. treat a Chinese medicine composition for allergic asthma, it is characterized in that said composition is made up of the component of following weight portion:
Radix Saposhnikoviae 10-15 weight portion, Folium Perillae 10-15 weight portion, Herba Ephedrae (processed) 2-6 weight portion, Fructus Schisandrae Chinensis 7-9 weight portion, Semen Ginkgo 7-9 weight portion, Semen Armeniacae Amarum 7-9 weight portion, Radix Asteris 7-9 weight portion, Fructus Corni 7-9 weight portion, Flos Magnoliae 7-9 weight portion.
2. the Chinese medicine composition for the treatment of allergic asthma according to claim 1, is characterized in that said composition is made up of the component of following weight portion:
Radix Saposhnikoviae 10-12 weight portion, Folium Perillae 10-12 weight portion, Herba Ephedrae (processed) 4-6 weight portion, Fructus Schisandrae Chinensis 7-8 weight portion, Semen Ginkgo 7-8 weight portion, Semen Armeniacae Amarum 7-8 weight portion, Radix Asteris 7-8 weight portion, Fructus Corni 7-8 weight portion, Flos Magnoliae 7-8 weight portion.
3. the Chinese medicine composition for the treatment of allergic asthma according to claim 1, is characterized in that said composition is made up of the component of following weight portion:
Radix Saposhnikoviae 10 weight portion, Folium Perillae 10 weight portion, Herba Ephedrae (processed) 6 weight portion, Fructus Schisandrae Chinensis 8 weight portion, Semen Ginkgo 8 weight portion, Semen Armeniacae Amarum 8 weight portion, Radix Asteris 8 weight portion, Fructus Corni 8 weight portion, Flos Magnoliae 8 weight portion.
4. the Chinese medicine composition of the treatment allergic asthma according to claim 1,2 or 3, it is characterized in that said composition add pharmacy allow adjuvant prepare decoction, granule, capsule, tablet or pill.
5. a preparation method for the Chinese medicine composition described in claim 1,2 or 3, is characterized in that it comprises the steps:
By Folium Perillae, Flos Magnoliae extraction by steam distillation volatile ingredient, for subsequent use after adopting beta-cyclodextrin inclusion compound, medicinal residues and Radix Saposhnikoviae, Herba Ephedrae (processed), Semen Armeniacae Amarum merge, decoct with water 2-3 time respectively, each 1-3 hour, merge extractive liquid, being condensed into relative density under 50 DEG C of conditions is the clear paste of 1.10 ~ 1.15, alcohol is sink to alcohol content 60%-70%, get supernatant concentration make relative density under 50 DEG C of conditions be 1.25 ~ 1.30 clear paste for subsequent use; Fructus Schisandrae Chinensis, Semen Ginkgo, Radix Asteris, Fructus Corni 60%-70% ethanol extraction 2-3 time, each 1-3 hour, merges alcohol extract, and concentrated to make relative density under 50 DEG C of conditions be the clear paste of 1.25 ~ 1.30; Merged by above-mentioned each clear paste, dry, pulverize, add volatile oil clathrate compound, mixing, to obtain final product.
6. a preparation method for Chinese medicine composition according to claim 5, is characterized in that it comprises the steps:
By Folium Perillae, Flos Magnoliae extraction by steam distillation volatile ingredient, for subsequent use after adopting beta-cyclodextrin inclusion compound, medicinal residues and Radix Saposhnikoviae, Herba Ephedrae (processed), Semen Armeniacae Amarum merge, add 10 times amount soak by water 3 times respectively, each 1.5 hours, merge extractive liquid, being condensed into relative density under 50 DEG C of conditions is the clear paste of 1.10 ~ 1.15, alcohol is sink to alcohol content 70%, get supernatant concentration make relative density under 50 DEG C of conditions be 1.25 ~ 1.30 clear paste for subsequent use; Fructus Schisandrae Chinensis, Semen Ginkgo, Radix Asteris, Fructus Corni 60% ethanol extraction 3 times, each 2.5 hours, merge alcohol extract, and concentrated to make relative density under 50 DEG C of conditions be the clear paste of 1.25 ~ 1.30; Merged by above-mentioned each clear paste, dry, pulverize, add volatile oil clathrate compound, mixing, to obtain final product.
7. the application of the Chinese medicine composition described in claim 1,2 or 3 in the medicine of preparation treatment allergic asthma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510885057.9A CN105412281B (en) | 2015-12-06 | 2015-12-06 | A kind of Chinese medicine composition for treating allergic asthma and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510885057.9A CN105412281B (en) | 2015-12-06 | 2015-12-06 | A kind of Chinese medicine composition for treating allergic asthma and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105412281A true CN105412281A (en) | 2016-03-23 |
| CN105412281B CN105412281B (en) | 2018-02-13 |
Family
ID=55491130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510885057.9A Active CN105412281B (en) | 2015-12-06 | 2015-12-06 | A kind of Chinese medicine composition for treating allergic asthma and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105412281B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107648285A (en) * | 2017-10-26 | 2018-02-02 | 大连大学 | Chinese ephedra non-alkaloids component is preparing the application in treating allergic asthma medicine |
| CN107764924A (en) * | 2016-08-19 | 2018-03-06 | 江苏康缘药业股份有限公司 | The detection method of active ingredient in asthma particle |
| CN111317787A (en) * | 2020-03-25 | 2020-06-23 | 漳州片仔癀药业股份有限公司 | Application of traditional Chinese medicine composition and preparation thereof in preparation of medicine for treating bronchial asthma |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1266693A (en) * | 2000-03-03 | 2000-09-20 | 马桂玲 | Chinese medicinal composition for treating asthma and preparing process thereof |
| CN104983881A (en) * | 2015-07-01 | 2015-10-21 | 北京东方运嘉科技发展有限公司 | Traditional Chinese medicine composition for relieving cough and asthma as well as preparation method and application of traditional Chinese medicine composition |
-
2015
- 2015-12-06 CN CN201510885057.9A patent/CN105412281B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1266693A (en) * | 2000-03-03 | 2000-09-20 | 马桂玲 | Chinese medicinal composition for treating asthma and preparing process thereof |
| CN104983881A (en) * | 2015-07-01 | 2015-10-21 | 北京东方运嘉科技发展有限公司 | Traditional Chinese medicine composition for relieving cough and asthma as well as preparation method and application of traditional Chinese medicine composition |
Non-Patent Citations (2)
| Title |
|---|
| 仝小林，等: "论过敏性疾病的中医药治疗", 《上海中医药大学学报》 * |
| 李彦军: "从风论治过敏性哮喘的文献整理和实验研究", 《中国优秀硕士学位论文全文数据库医药卫生科技辑2010年第11期》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107764924A (en) * | 2016-08-19 | 2018-03-06 | 江苏康缘药业股份有限公司 | The detection method of active ingredient in asthma particle |
| CN107648285A (en) * | 2017-10-26 | 2018-02-02 | 大连大学 | Chinese ephedra non-alkaloids component is preparing the application in treating allergic asthma medicine |
| CN111317787A (en) * | 2020-03-25 | 2020-06-23 | 漳州片仔癀药业股份有限公司 | Application of traditional Chinese medicine composition and preparation thereof in preparation of medicine for treating bronchial asthma |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105412281B (en) | 2018-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106421039A (en) | Traditional Chinese medicine composition for preventing and treating haze-caused diseases, preparation method thereof and mask containing traditional Chinese medicine | |
| CN105412281A (en) | Traditional Chinese medicinal composition for treating allergic asthma and preparation method thereof | |
| CN105233231A (en) | Pharmaceutical composition for treating respiratory diseases | |
| CN103961614B (en) | Chinese medicine composition for treating respiratory disease and its production and use | |
| CN103977315B (en) | Medicinal composition for treating cough with wind-heat affecting lung and preparation method thereof | |
| CN101474377A (en) | Chinese medicine prescription for treating chronic bronchitis | |
| CN103142842A (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN101549059B (en) | Medicament for treating bronchial asthma and preparation method thereof | |
| CN104940485A (en) | Traditional Chinese medicine composition for treating infantile asthma and preparation method thereof | |
| CN103446414B (en) | Xiangmahanchuantie (XMHCT) and preparation technology | |
| CN105497723A (en) | Traditional Chinese medicine preparation for treating bacterial pneumonia and preparation method thereof | |
| CN108743893A (en) | The preparation method and applications of clearing lung-heat soup side's Chinese medical extract | |
| CN101244199B (en) | Chinese medicine pill for treating bronchial asthma, chronic bronchitis | |
| CN114558049A (en) | Traditional Chinese medicine prescription for treating Chronic Obstructive Pulmonary Disease (COPD) stable phase series and application | |
| CN104740581B (en) | A kind of application of cold asthma patch of fragrant fiber crops and its detection method | |
| CN103463604A (en) | Drug for treating cough and asthma | |
| CN101143199A (en) | Traditional Chinese medicine for treating chronic bronchitis | |
| CN105012819B (en) | A kind of pharmaceutical preparation for bronchial asthma | |
| CN104127544B (en) | The application in preparing medicine of Murraya tetramera Huang and extract thereof | |
| CN107582834A (en) | A kind of Chinese medicine composition for treating empty asthma | |
| CN103099877B (en) | Traditional Chinese medicine formula for treating and preventing children asthmatic disease | |
| CN104383238A (en) | Medicine for treating bronchial asthma | |
| CN105327198A (en) | Heat-clearing and cough-relieving health care tea and preparation method and application thereof | |
| CN105902735A (en) | Traditional Chinese medicine composition for treating asthmatic bronchitis | |
| CN105168860A (en) | Traditional Chinese medicine composite for treating infantile asthma and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |